Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maureen E Lane

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Biochemical Pharmacology|September 18, 2002
SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cellsBo Yu, Maureen E Lane, Scott Wadler
Seminars in Respiratory and Critical Care Medicine|July 25, 2008
Lung biopsy: special techniquesMatthew D Cham, Maureen E Lane, Claudia I Henschke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studiesDella Makower, Alla Rozenblit, Howard Kaufman, et al.
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|March 28, 2003
Clinical applications of p53-directed gene therapyScott Wadler, Della Makower, Bo Yu, et al.
Annals of Clinical and Translational Neurology|December 11, 2014
Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patientsGigi J Ebenezer, Karen Carlson, Diana Donovan, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2010
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancerAllyson J Ocean, Paul Christos, Joseph A Sparano, et al.
BMC Cancer|April 18, 2015
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicitySasha E Stanton, Maureen M Ward, Paul Christos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilizationRuben Niesvizky, Tomer M Mark, Maureen Ward, et al.
Breast Cancer Research and Treatment|December 14, 2011
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patientsSarika Jain, Maureen M Ward, Jennifer O'Loughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancerNasser Altorki, Maureen E Lane, Thomas Bauer, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Biochemical Pharmacology|September 18, 2002
SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cellsBo Yu, Maureen E Lane, Scott Wadler
Seminars in Respiratory and Critical Care Medicine|July 25, 2008
Lung biopsy: special techniquesMatthew D Cham, Maureen E Lane, Claudia I Henschke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studiesDella Makower, Alla Rozenblit, Howard Kaufman, et al.
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|March 28, 2003
Clinical applications of p53-directed gene therapyScott Wadler, Della Makower, Bo Yu, et al.
Annals of Clinical and Translational Neurology|December 11, 2014
Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patientsGigi J Ebenezer, Karen Carlson, Diana Donovan, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2010
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancerAllyson J Ocean, Paul Christos, Joseph A Sparano, et al.
BMC Cancer|April 18, 2015
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicitySasha E Stanton, Maureen M Ward, Paul Christos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilizationRuben Niesvizky, Tomer M Mark, Maureen Ward, et al.
Breast Cancer Research and Treatment|December 14, 2011
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patientsSarika Jain, Maureen M Ward, Jennifer O'Loughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancerNasser Altorki, Maureen E Lane, Thomas Bauer, et al.
Pageof 2